6 May 2021
Dr Tom Mules speaks to RNZ about how human hookworms show a remarkable ability to dampen down aggressive immune responses, offering an exciting potential for treating autoimmune or inflammatory diseases.
The Malaghan Institute's hookworm clinical therapy programme aims to explore the therapeutic benefits of the human hookworm necator americanus.
This Health Research Council funded programme involves infecting volunteers with a controlled dose of hookworm, and monitoring how they affect their hosts' health and immune profile. The study has since moved onto working with patients with ulcerative colitis, with plans to expand the programme further in the future.
Malaghan Institute clinical consultant Dr Tom Mules, a gastroenterologist in the Wellington region who is working on the hookworm programme, sat down with RNZ to discuss the wider programme and our motivations for conducting this study.
Related articles
Study shows link between prenatal antibiotic exposure and allergic diseases
18 July 2022
Dr Kerry Hilligan awarded HRC Emerging Researcher First Grant
31 May 2022
In focus: Making friends with enemies, unexpected solutions to our allergy epidemic
16 February 2022
Discovery points to the skin as ‘ground zero’ for allergic disease
19 November 2021
Study finds a high-fibre diet can improve immune response to vaccines
18 November 2021
Could a dose of worms be the answer to treating incurable autoimmune diseases?
14 November 2021